Clinical experience with the micronucleus assay

Area of Science:

• Oncology
• Genetics
• Cell Biology

Background:

• Cancer prevention trials often face logistical challenges making cancer incidence an impractical endpoint.
• There is a critical need for reliable intermediate markers (surrogate endpoints) to assess cancer risk in chemoprevention studies.
• Few potential intermediate markers have undergone rigorous validation for clinical application.

Purpose of the Study:

• To evaluate the utility of micronuclei frequency in exfoliated buccal mucosal cells as a surrogate endpoint for oral cancer chemoprevention trials.
• To standardize the micronucleus assay for consistent application in clinical research.

Main Methods:

• Standardized the definition of a micronucleus through literature review and inter-investigator slide exchange.
• Collected exfoliated buccal cell smears from normal subjects, smokers (with/without leukoplakia), and tobacco chewers (with/without leukoplakia).
• Analyzed smears for micronuclei frequency and other cytological abnormalities.

Main Results:

• Micronuclei are among several cytological abnormalities observed in exfoliated buccal cells.
• Tobacco chewers exhibited a high frequency of various abnormalities, including micronuclei, anucleate, binucleate, and multinucleated cells, and abnormal nuclear morphology.
• The study focused on the buccal mucosa due to available data and its relevance to oral cancer prevention.

Conclusions:

• The micronucleus assay, when standardized, shows promise as a surrogate endpoint in oral cancer chemoprevention.
• Further validation is needed, but the assay can detect cytological changes associated with tobacco use.
• The findings support the use of buccal cell micronuclei analysis in assessing risk and intervention effectiveness.